Butterfly Launches Handheld Ultrasound Devices in Brazil
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Market Expansion: Butterfly Network's launch of its handheld ultrasound devices iQ+ and iQ3 in Brazil marks a significant step in its international growth strategy, as Brazil represents the largest medical device market in Latin America with substantial market potential.
- Technological Advantage: By successfully meeting Brazil's regulatory and certification requirements, Butterfly demonstrates the strength of its ultrasound technology, providing reliable solutions for clinicians in high-standard markets, thereby enhancing its competitive edge.
- Improved Accessibility: The introduction of these devices not only increases diagnostic capacity in high-volume hospitals and emergency settings but also improves healthcare access in underserved rural communities, enabling more patients to receive timely medical imaging.
- Global Footprint Expansion: The commercial launch in Brazil further extends Butterfly's global market presence, supporting its mission to increase access to its technology in key international markets and advance the democratization of medical imaging.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.930
Low
4.00
Averages
4.25
High
4.50
Current: 7.930
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Butterfly Network Executive Sells 399,461 Shares in Major Transaction
- Executive Stock Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of Common Stock on June 5 and 8 for approximately $1.89 million, indicating a potential lack of confidence in the company's future prospects.
- Largest Single Transaction: This sale marks Cashman's largest open-market transaction to date, surpassing his previous maximum of 250,000 shares sold on February 26, 2026, suggesting that his decisions may be influenced by market volatility.
- Change in Ownership Proportion: The sale represented 19.68% of his direct holdings, leaving him with 1,630,407 shares post-transaction, which indicates his continued significant position in the company but raises questions about his future intentions regarding ownership.
- Market Reaction and Risks: Despite Butterfly Network's revenue growth of 19% in 2025 and 25% in Q1 2026, there are doubts about whether the stock's rapid rise reflects genuine business improvement, particularly given the concentration risk associated with its licensing deal with Midjourney, which could impact future growth potential.
See More
Butterfly Network Executive Sells 399K Shares
- Executive Sell-off Scale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of common stock on June 5 and 8, 2026, totaling approximately $1.89 million, marking his largest single open-market sale to date, exceeding his previous maximum of 250,000 shares, indicating a cautious outlook on the company's future.
- Shareholding Proportion Change: This sale represented 19.68% of Cashman's direct holdings, leaving him with 1,630,407 shares post-transaction, suggesting that despite the sell-off, he maintains a significant stake in the company, which could influence market confidence.
- Market Reaction Analysis: Although Butterfly Network's revenue grew by 19% in 2025 and 25% in Q1 2026, the market's rapid price increase raises concerns, as a significant portion of future revenue is tied to a licensing deal with Midjourney, presenting a concentration risk for investors.
- Investor Strategy Recommendation: Analysts advise investors to exercise patience when considering Butterfly Network stock, especially given the stable performance of its core ultrasound business, as the sustainability of recent licensing revenue remains to be seen amid the stock's recent price surge.
See More
Butterfly Launches Handheld Ultrasound Devices in Brazil
- Market Expansion: Butterfly Network's launch of its handheld ultrasound devices iQ+ and iQ3 in Brazil marks a significant step in its international growth strategy, as Brazil represents the largest medical device market in Latin America with substantial market potential.
- Technological Advantage: By successfully meeting Brazil's regulatory and certification requirements, Butterfly demonstrates the strength of its ultrasound technology, providing reliable solutions for clinicians in high-standard markets, thereby enhancing its competitive edge.
- Improved Accessibility: The introduction of these devices not only increases diagnostic capacity in high-volume hospitals and emergency settings but also improves healthcare access in underserved rural communities, enabling more patients to receive timely medical imaging.
- Global Footprint Expansion: The commercial launch in Brazil further extends Butterfly's global market presence, supporting its mission to increase access to its technology in key international markets and advance the democratization of medical imaging.
See More
Jim Cramer Endorses Medline as Best IPO of the Year
- IPO Outlook: Jim Cramer identifies Medline as the best IPO of the year, indicating strong market confidence in its future performance, which may attract more investor interest.
- Investment Recommendation: Cramer explicitly endorses Medline on his show, emphasizing its investment value, which could drive stock price increases and bolster market confidence.
- Positive Market Reaction: Medline's performance gains recognition from Cramer, potentially prompting more analysts to focus on it and provide favorable evaluations, thereby enhancing its market position.
- Risk and Opportunity: While Cramer mentions Nuscale Power as speculative, his positive view on Medline highlights its relative safety in the current market environment, appealing to risk-averse investors.
See More
Midjourney Launches New Medical Imaging Technology
- Strategic Partnership Outlook: The collaboration between Midjourney and Butterfly Network is expected to generate up to $74 million in revenue over five years, significantly enhancing Butterfly's financial performance and market position.
- Imaging Innovation: Midjourney's new whole-body scanner utilizes 40 proprietary Ultrasound-on-Chip modules, aiming to produce detailed body images in 60 seconds, which could drastically lower imaging costs and improve accessibility, potentially reshaping the medical imaging industry.
- Market Expansion Plans: Midjourney plans to open its first spa in San Francisco in 2027, combining traditional spa amenities with routine body scanning, and aims to operate over 50,000 scanners worldwide by 2031, with a monthly scanning capacity of up to one billion scans.
- Surge in Investor Sentiment: BFLY shares surged 56% on Thursday and have increased 312% over the past year, with retail investor sentiment jumping from 'bullish' to 'extremely bullish', reflecting strong confidence in the company's future growth potential.
See More
Multiple Companies Show Strong Stock Performance
- Butterfly Network Stock Surge: Butterfly Network's stock has risen 304% since publication, currently priced at $8.90, driven by the successful application of its Ultrasound-on-Chip technology and collaboration with Midjourney, with a full-body imaging system launch expected to boost market demand.
- Nuvectis Pharma Significant Progress: Nuvectis's NXP900 clinical program is advancing at top US hospitals, with a stock price increase of 104%, currently at $13.82, and preliminary data expected this summer, likely attracting investor interest.
- Trevi Therapeutics Clinical Trial Success: Trevi's Haduvio drug achieved positive results in the Phase 2b CORAL trial, with a stock price increase of 167%, currently at $17.21, and plans for two Phase 3 trials in 2026, indicating strong market potential.
- BrightSpring Health Service Growth: BrightSpring's stock has risen 291% since publication, currently priced at $66.25, as the company's operational and financial performance has drawn investor attention, with second-quarter results due in August, potentially revising 2026 revenue guidance upward.
See More
Butterfly Network Executive Sells 399,461 Shares in Major Transaction
- Executive Stock Sale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of Common Stock on June 5 and 8 for approximately $1.89 million, indicating a potential lack of confidence in the company's future prospects.
- Largest Single Transaction: This sale marks Cashman's largest open-market transaction to date, surpassing his previous maximum of 250,000 shares sold on February 26, 2026, suggesting that his decisions may be influenced by market volatility.
- Change in Ownership Proportion: The sale represented 19.68% of his direct holdings, leaving him with 1,630,407 shares post-transaction, which indicates his continued significant position in the company but raises questions about his future intentions regarding ownership.
- Market Reaction and Risks: Despite Butterfly Network's revenue growth of 19% in 2025 and 25% in Q1 2026, there are doubts about whether the stock's rapid rise reflects genuine business improvement, particularly given the concentration risk associated with its licensing deal with Midjourney, which could impact future growth potential.
See More
Butterfly Network Executive Sells 399K Shares
- Executive Sell-off Scale: Butterfly Network's Chief Business Officer Steve Cashman disclosed the direct sale of 399,461 shares of common stock on June 5 and 8, 2026, totaling approximately $1.89 million, marking his largest single open-market sale to date, exceeding his previous maximum of 250,000 shares, indicating a cautious outlook on the company's future.
- Shareholding Proportion Change: This sale represented 19.68% of Cashman's direct holdings, leaving him with 1,630,407 shares post-transaction, suggesting that despite the sell-off, he maintains a significant stake in the company, which could influence market confidence.
- Market Reaction Analysis: Although Butterfly Network's revenue grew by 19% in 2025 and 25% in Q1 2026, the market's rapid price increase raises concerns, as a significant portion of future revenue is tied to a licensing deal with Midjourney, presenting a concentration risk for investors.
- Investor Strategy Recommendation: Analysts advise investors to exercise patience when considering Butterfly Network stock, especially given the stable performance of its core ultrasound business, as the sustainability of recent licensing revenue remains to be seen amid the stock's recent price surge.
See More
Butterfly Launches Handheld Ultrasound Devices in Brazil
- Market Expansion: Butterfly Network's launch of its handheld ultrasound devices iQ+ and iQ3 in Brazil marks a significant step in its international growth strategy, as Brazil represents the largest medical device market in Latin America with substantial market potential.
- Technological Advantage: By successfully meeting Brazil's regulatory and certification requirements, Butterfly demonstrates the strength of its ultrasound technology, providing reliable solutions for clinicians in high-standard markets, thereby enhancing its competitive edge.
- Improved Accessibility: The introduction of these devices not only increases diagnostic capacity in high-volume hospitals and emergency settings but also improves healthcare access in underserved rural communities, enabling more patients to receive timely medical imaging.
- Global Footprint Expansion: The commercial launch in Brazil further extends Butterfly's global market presence, supporting its mission to increase access to its technology in key international markets and advance the democratization of medical imaging.
See More
Jim Cramer Endorses Medline as Best IPO of the Year
- IPO Outlook: Jim Cramer identifies Medline as the best IPO of the year, indicating strong market confidence in its future performance, which may attract more investor interest.
- Investment Recommendation: Cramer explicitly endorses Medline on his show, emphasizing its investment value, which could drive stock price increases and bolster market confidence.
- Positive Market Reaction: Medline's performance gains recognition from Cramer, potentially prompting more analysts to focus on it and provide favorable evaluations, thereby enhancing its market position.
- Risk and Opportunity: While Cramer mentions Nuscale Power as speculative, his positive view on Medline highlights its relative safety in the current market environment, appealing to risk-averse investors.
See More
Midjourney Launches New Medical Imaging Technology
- Strategic Partnership Outlook: The collaboration between Midjourney and Butterfly Network is expected to generate up to $74 million in revenue over five years, significantly enhancing Butterfly's financial performance and market position.
- Imaging Innovation: Midjourney's new whole-body scanner utilizes 40 proprietary Ultrasound-on-Chip modules, aiming to produce detailed body images in 60 seconds, which could drastically lower imaging costs and improve accessibility, potentially reshaping the medical imaging industry.
- Market Expansion Plans: Midjourney plans to open its first spa in San Francisco in 2027, combining traditional spa amenities with routine body scanning, and aims to operate over 50,000 scanners worldwide by 2031, with a monthly scanning capacity of up to one billion scans.
- Surge in Investor Sentiment: BFLY shares surged 56% on Thursday and have increased 312% over the past year, with retail investor sentiment jumping from 'bullish' to 'extremely bullish', reflecting strong confidence in the company's future growth potential.
See More
Multiple Companies Show Strong Stock Performance
- Butterfly Network Stock Surge: Butterfly Network's stock has risen 304% since publication, currently priced at $8.90, driven by the successful application of its Ultrasound-on-Chip technology and collaboration with Midjourney, with a full-body imaging system launch expected to boost market demand.
- Nuvectis Pharma Significant Progress: Nuvectis's NXP900 clinical program is advancing at top US hospitals, with a stock price increase of 104%, currently at $13.82, and preliminary data expected this summer, likely attracting investor interest.
- Trevi Therapeutics Clinical Trial Success: Trevi's Haduvio drug achieved positive results in the Phase 2b CORAL trial, with a stock price increase of 167%, currently at $17.21, and plans for two Phase 3 trials in 2026, indicating strong market potential.
- BrightSpring Health Service Growth: BrightSpring's stock has risen 291% since publication, currently priced at $66.25, as the company's operational and financial performance has drawn investor attention, with second-quarter results due in August, potentially revising 2026 revenue guidance upward.
See More
